SYRE — Spyre Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Spyre Therapeutics Files For Mixed Shelf Offering Of Up To $500 Million- SEC Filing
Spyre Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Spyre Therapeutics Inc expected to post a loss of 99 cents a share - Earnings Preview
Brief: Spyre Therapeutics Added To The Nasdaq Biotechnology Index
Brief: Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
Brief: Spyre Therapeutics Announces Pricing Of $200 Mln Public Offering Of Common Stock At $27.50 Per Share
Brief: Spyre Therapeutics Inc - SPY001 Well Tolerated With Favorable Safety Profile
Spyre Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
U.S. RESEARCH ROUNDUP- Cadence Design Systems, Equity Bancshares, S&P Global
Brief: Spyre Therapeutics Spy003 First-In-Human Dosing Now Expected Q1 2025
Brief: Spyre Therapeutics Inc Files For Offering Of Upto 46.3 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
Spyre Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Spyre Therapeutics Inc expected to post a loss of 95 cents a share - Earnings Preview
Brief: Spyre Therapeutics Announces First Participants Dosed In Phase 1 Trial Of Spy001, It's Inflammatory Bowel Disease Treatment
Brief: Spyre Therapeutics Appoints Dr. Sandra Milligan to Board of Directors
Spyre Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Spyre Therapeutics Inc expected to post a loss of $1.17 a share - Earnings Preview
Brief: Spyre Therapeutics Announces $180 Million Private Placement
Spyre Therapeutics Inc reports results for the quarter ended in December - Earnings Summary